Literature DB >> 28138813

Noninvasive PET quantitative myocardial blood flow with regadenoson for assessing cardiac allograft vasculopathy in orthotopic heart transplantation patients.

Miguel Hernandez Pampaloni1, Uttam M Shrestha2, Maria Sciammarella3, Youngho Seo1, Grant T Gullberg1, Elias H Botvinick1,3.   

Abstract

BACKGROUND: Risk stratification and early detection of cardiac allograft vasculopathy (CAV) is essential in orthotopic heart transplantation (OHT) patients. This study assesses the changes in myocardial blood flow (MBF) noninvasively in OHT patients using quantitative cardiac PET with regadenoson.
METHODS: Twelve patients (Group 1) (8 males, 4 females, mean age 55 ± 7 years) with no history of post OHT myocardial ischemia were enrolled 5.4 ± 2.0 years after OHT. Fifteen patients (Group 2) (9 males, 6 females, mean age 71 ± 9 years) with intermediate pretest probability but not documented evidence for coronary artery disease (CAD) were also included to serve as control. Global and regional MBFs were assessed using dynamic 13N-NH3 PET at rest and during regadenoson-induced hyperemia. The coronary flow reserve (CFR) was also calculated as the ratio of hyperemic to resting MBF.
RESULTS: Mean regadenoson-induced rate-pressure products were similar in both groups, while there was an increase in resting rate-pressure product in Group 1 patients. Both mean and median values of resting MBF were higher in Group 1 than Group 2 patients (1.33 ± 0.31 and 1.01 ± 0.21 mL/min/g for Groups 1 and 2, respectively, P < .001), while mean hyperemic MBF values were similar in both Groups (2.68 ± 0.84 and 2.64 ± 0.94 mL/min/g, P = NS) but median hyperemic MBF values were lower in Group 1 than Group 2 patients (2.0 vs. 2.60 mL/min/g, P = .018). Both mean and median CFR values demonstrated a significant reduction for Group 1 compared to Group 2 patients (2.07 ± 0.74 vs 2.63 ± 0.48, P = .025).
CONCLUSIONS: This study suggests that the MBF in OHT patients may be abnormal at resting state with diminished CFR. This hints that the epicardial and microvascular coronary subsystem may be exacerbated after OHT leading to the gradual progression of CAV.

Entities:  

Keywords:  Dynamic PET; cardiac allograft vasculopathy; coronary flow reserve; orthotopic heart transplant; regadenoson

Mesh:

Substances:

Year:  2017        PMID: 28138813      PMCID: PMC5534390          DOI: 10.1007/s12350-016-0761-3

Source DB:  PubMed          Journal:  J Nucl Cardiol        ISSN: 1071-3581            Impact factor:   5.952


  32 in total

1.  Angiographic assessment of cardiac allograft vasculopathy: results of a Consensus Conference of the Task Force for Thoracic Organ Transplantation of the German Cardiac Society.

Authors:  Ernst Wellnhofer; Jörg Stypmann; Christoph L Bara; Thomas Stadlbauer; Martin C Heidt; Hans U Kreider-Stempfle; Hae-Young Sohn; Wolfgang Zeh; Thomas Comberg; Siegfried Eckert; Thomas Dengler; Stephan M Ensminger; Nicola E Hiemann
Journal:  Transpl Int       Date:  2010-08-19       Impact factor: 3.782

Review 2.  Transplant coronary artery disease.

Authors:  Raymond J Zimmer; Michael S Lee
Journal:  JACC Cardiovasc Interv       Date:  2010-04       Impact factor: 11.195

3.  The effect of regadenoson-induced transient disruption of the blood-brain barrier on temozolomide delivery to normal rat brain.

Authors:  Sadhana Jackson; Nicole M Anders; Antonella Mangraviti; Teresia M Wanjiku; Eric W Sankey; Ann Liu; Henry Brem; Betty Tyler; Michelle A Rudek; Stuart A Grossman
Journal:  J Neurooncol       Date:  2015-12-01       Impact factor: 4.130

4.  Noninvasive quantification of regional blood flow in the human heart using N-13 ammonia and dynamic positron emission tomographic imaging.

Authors:  G D Hutchins; M Schwaiger; K C Rosenspire; J Krivokapich; H Schelbert; D E Kuhl
Journal:  J Am Coll Cardiol       Date:  1990-04       Impact factor: 24.094

5.  Coronary endothelial dysfunction after heart transplantation predicts allograft vasculopathy and cardiac death.

Authors:  S M Hollenberg; L W Klein; J E Parrillo; M Scherer; D Burns; P Tamburro; M Oberoi; M R Johnson; M R Costanzo
Journal:  Circulation       Date:  2001-12-18       Impact factor: 29.690

6.  Progressive coronary luminal narrowing after cardiac transplantation.

Authors:  S Z Gao; E L Alderman; J S Schroeder; S A Hunt; V Wiederhold; E B Stinson
Journal:  Circulation       Date:  1990-11       Impact factor: 29.690

7.  Evidence for structural sympathetic reinnervation after orthotopic cardiac transplantation in humans.

Authors:  R F Wilson; B V Christensen; M T Olivari; A Simon; C W White; D D Laxson
Journal:  Circulation       Date:  1991-04       Impact factor: 29.690

8.  Relationship between coronary function by positron emission tomography and temporal changes in morphology by intravascular ultrasound (IVUS) in transplant recipients.

Authors:  M Allen-Auerbach; H Schöder; J Johnson; K Kofoed; K Einhorn; M E Phelps; J Kobashigawa; J Czernin
Journal:  J Heart Lung Transplant       Date:  1999-03       Impact factor: 10.247

9.  Prevalence of accelerated coronary artery disease in heart transplant survivors. Comparison of cyclosporine and azathioprine regimens.

Authors:  S Z Gao; J S Schroeder; E L Alderman; S A Hunt; H A Valantine; V Wiederhold; E B Stinson
Journal:  Circulation       Date:  1989-11       Impact factor: 29.690

10.  Effects of age, gender, obesity, and diabetes on the efficacy and safety of the selective A2A agonist regadenoson versus adenosine in myocardial perfusion imaging integrated ADVANCE-MPI trial results.

Authors:  Manuel D Cerqueira; Patricia Nguyen; Peter Staehr; S Richard Underwood; Ami E Iskandrian
Journal:  JACC Cardiovasc Imaging       Date:  2008-05
View more
  8 in total

1.  Regadenoson-induced hyperemia for absolute myocardial blood flow quantitation by 13N-ammonia PET and detection of cardiac allograft vasculopathy.

Authors:  René R Sevag Packard; Jamshid Maddahi
Journal:  J Nucl Cardiol       Date:  2017-01-30       Impact factor: 5.952

Review 2.  Review of cardiovascular imaging in the Journal of Nuclear Cardiology 2017. Part 1 of 2: Positron emission tomography, computed tomography, and magnetic resonance.

Authors:  Wael A AlJaroudi; Fadi G Hage
Journal:  J Nucl Cardiol       Date:  2017-11-08       Impact factor: 5.952

Review 3.  The role of non-invasive imaging modalities in cardiac allograft vasculopathy: an updated focus on current evidences.

Authors:  C Sciaccaluga; N Ghionzoli; G E Mandoli; N Sisti; F D'Ascenzi; M Focardi; S Bernazzali; G Vergaro; M Emdin; S Valente; M Cameli
Journal:  Heart Fail Rev       Date:  2021-08-12       Impact factor: 4.654

4.  Prediction of long-term (> 10 year) cardiovascular outcomes in heart transplant recipients: Value of stress technetium-99m tetrofosmin myocardial perfusion imaging.

Authors:  Jesse F Veenis; Hendrik J Boiten; Jan C van den Berge; Kadir Caliskan; Alex P W M Maat; Roelf Valkema; Alina A Constantinescu; Olivier C Manintveld; Felix Zijlstra; Ron T van Domburg; Arend F L Schinkel
Journal:  J Nucl Cardiol       Date:  2017-11-07       Impact factor: 5.952

5.  Comprehensive morphologic and functional imaging of heart transplant patients: first experience with dynamic perfusion CT.

Authors:  S Oebel; S Hamada; K Higashigaito; J von Spiczak; E Klotz; F Enseleit; R Hinzpeter; F Ruschitzka; R Manka; H Alkadhi
Journal:  Eur Radiol       Date:  2018-04-30       Impact factor: 5.315

6.  Quantitative Assessment of Myocardial Ischemia With Positron Emission Tomography.

Authors:  Jae Ho Sohn; Spencer C Behr; Miguel Hernandez Pampaloni; Youngho Seo
Journal:  J Thorac Imaging       Date:  2021-01-22       Impact factor: 5.528

7.  Assessment of late-term progression of cardiac allograft vasculopathy in patients with orthotopic heart transplantation using quantitative cardiac 82Rb PET.

Authors:  Uttam M Shrestha; Maria Sciammarella; Miguel Hernandez Pampaloni; Elias H Botvinick; Grant T Gullberg; Teresa DeMarco; Youngho Seo
Journal:  Int J Cardiovasc Imaging       Date:  2020-10-29       Impact factor: 2.357

8.  Quantitative myocardial perfusion response to adenosine and regadenoson in patients with suspected coronary artery disease.

Authors:  Mark Lubberink; Juhani Knuuti; Tanja Kero; Antti Saraste; Bo Lagerqvist; Jens Sörensen; Essi Pikkarainen
Journal:  J Nucl Cardiol       Date:  2021-08-12       Impact factor: 5.952

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.